Boulder-based biopharmaceutical company Clovis Oncology Inc. (Nasdaq: CLVS) announced on Monday that chief medical officer Andrew Allen will leave in August to create a new company.
Senior vice president of clinical development Lindsey Rolfe, who oversees development of cancer drug candidates rociletinib and rucaparib, has been named as Allen’s replacement.
But living with cancer is a life change. It could mean an inability to work and function. Even with health insurance, some patients struggle to make ends meet. That’s where our cancer patient and family assistance fund comes in.
Clovis officials did not name Allen’s new company, stating only that it would be an “immuno-oncology focused biotechnology company.” Allen will serve was CEO.
Allen’s departure will come once Clovis has submitted its New Drug Application for rociletinib with the U.S. Food and Drug Administration, as well as a Marketing Authorization Application with the European Medicines Agency.
“I’ve loved working with Andrew at Clovis, and before that at our prior company, but I always knew this day would come and that Andrew would eventually pursue his interesting in starting and running his own company,” Clovis CEO Pat Mahaffy said in a press release.
Rolfe has been with Clovis since 2010, following stints at Celgene, Pharmion and multiple other companies. As CMO, she will oversee clinical development, preclinical development, clinical operations and pharmacovigilance. She will be based in the company’s San Francisco office.
Clovis’s share price was unchanged Monday, closing at $93.19, even with Friday’s close.